First of all, presence of rare mutations rendering tumor responsiveness to conventional EGFR TKIs (gefitinib, erlotinib, afatinib, osimertinib, etc.)cannot be reliably excluded using mutation-specific PCR. This evidence concerns the gene EGFR and neoplasm.